Regulatory Framework for Platform Technologies

adobestock_237602801_optimized

Source: Adobe Stock

Several novel manufacturing technologies and platforms, for example, messenger ribonucleic acid (mRNA) platform, synthetic DNA (doggybone (dbDNA)) platform, have recently emerged to produce vaccines and advanced therapy medicinal products (ATMPs) for human use. However, the regulatory framework for such platform technologies is not fully developed. There is significant interest in utilising platform approaches for drug development and for the commercial production of human medicines. Thus, some form of regulatory guidance and pathway, similar to the EU platform technology master le (PTMF) system that is used in the regulatory approval of veterinary vaccines, would benefit the human vaccines industry.

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

Not a TOPRA member yet? 

Join now to get access to:

  • Features and specialist articles
  • CPD supplements
  • Comprehensive archive

Not sure yet?  Read one of our free editorials to see what you’re missing out on!